Peijia Medical Limited

Equities

9996

KYG6981F1090

Medical Equipment, Supplies & Distribution

Delayed Hong Kong S.E. Other stock markets 04:08:03 2024-03-28 am EDT			5-day change	1st Jan Change
3.66 ^HKD	-3.94%		-.--%	-50.47%

Apr. 08	JenaValve Technology, Inc. announced that it has received $100.4 million in funding from a group of investors	CI
Apr. 02	Peijia Medical Limited Delays in Publication of 2023 Annual Results	CI

Peijia Medical Limited Announces Successful Completion of First Two Commercial Implantations of TaurusOne in Xiamen Cardiovascular Hospital of Xiamen University

June 31, 2021 at 06:08 pm EDT

The board of directors of Peijia Medical Limited announced that on May 31, 2021, the company successfully completed the first two commercial implantations of TaurusOne® in Xiamen Cardiovascular Hospital of Xiamen University. TaurusOne® is the company's first-generation transcatheter aortic valve replacement (TAVR) device and core product.

Latest news about Peijia Medical Limited

JenaValve Technology, Inc. announced that it has received $100.4 million in funding from a group of investors	Apr. 07	CI
Peijia Medical Limited Delays in Publication of 2023 Annual Results	Apr. 01	CI
Peijia Medical Narrows 2023 Loss as Revenue Jumps 76%	Apr. 01	MT
Peijia Medical Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial	Jan. 29	CI
Peijia Medical's 2023 Profit to Jump Up to 79.4%	Jan. 26	MT
Peijia Medical Limited Announces Unaudited Revenue Results for the Year Ended December 31, 2023	Jan. 25	CI
Peijia Medical's Stock Jumps on Positive Updates For Two Devices	23-10-27	MT
Peijia Medical Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Peijia Medical Enrolls First Patient in TaurusTrio Transcatheter System; Shares Up 4%	23-08-01	MT
Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio?? Transcatheter Aortic Valve Replacement System in China	23-07-31	CI
Peijia Medical's H1 Revenue Rises By Up to 94%	23-07-21	MT
Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023	23-07-21	CI
China Approves Peijia Medical Unit's Micro Guidewire for Neuro-Intervention Operations	23-07-06	MT
Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire	23-07-06	CI
Peijia Medical Completes Two Commercial Implants with Trilogy System in Hong Kong	23-05-15	MT
Peijia Medical's 2022 Loss Narrows 29%	23-04-03	MT
Peijia Medical Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Peijia Medical's 2022 Revenue Surges Up to 90.4%	23-01-17	MT
Peijia Medical Limited Reports Unaudited Operating Statistics for the Year Ended December 31, 2022	23-01-17	CI
Peijia Medical Enrolls First Patient in Transcatheter Repair System Clinical Trial in China	22-12-04	MT
Peijia Medical Limited Announces First Patient Enrollment in the Multi-Center Registration Clinical Trial of Geminione Transcatheter Edge-To-Edge Repair System in China	22-12-04	CI
Peijia Medical Completes First Patient Implant in Transcatheter Tricuspid Valve Replacement System Trial	22-11-24	MT
Peijia Medical Limited Announces in Partnership with inQB8 Medical Technologies, LLC Successfully Completed the First Patient Implant in the First-In-Man Clinical Trial of the MonarQ Transcatheter Tricuspid Valve Replacement System in the World	22-11-24	CI
Peijia Medical Enrolls First Patient in China Clinical Trial for Mitral Valve Replacement; Shares Climb 4%	22-11-13	MT

Chart Peijia Medical Limited

Duration

Period

More charts

Company Profile

Peijia Medical Ltd is a China-based holding company mainly engaged in the research and development of interventional procedural medical devices. Through its subsidiaries, the Company operates two segments. Transcatheter Valve Therapeutic Business segment is mainly engaged in the development of transcatheter valve therapeutic medical devices. Neurointerventional Business segment is engaged in the research and development of neurointerventional procedural medical devices. The Company's main products under development include TaurusOne, TaurusElite, TaurusNXT and others. The Company operates its businesses primarily in domestic market.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Peijia Medical Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.38 CNY

Average target price

11.1 CNY

Spread / Average Target

+228.38%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
PEIJIA MEDICAL LIMITED	-50.47%	316M
STRYKER CORPORATION	+12.59%	128B
SMITH & NEPHEW PLC	-10.58%	10.66B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-0.39%	8.55B
INSPIRE MEDICAL SYSTEMS, INC.	+13.56%	7.1B
GLAUKOS CORPORATION	+25.94%	5.06B
AXONICS, INC.	+6.93%	3.4B
ENOVIS CORPORATION	-1.64%	3.08B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-11.96%	2.11B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-7.25%	2.03B

Medical Devices & Implants